Daniel T O'Connor

US Patent:

20070087020, Apr 19, 2007

Filed:

Jan 27, 2006

Appl. No.:

11/340507

Inventors:

Daniel O'Connor - Princeton NJ, US

International Classification:

A61K 39/002

US Classification:

424265100

Abstract:

The present invention describes using, on a repetitive basis, a non-human colonizing helminth compound, in an amount sufficient to establish a transitory parasitic helminth infection and or to simulate in a parasitic helminth infection, thereby having immunosuppressive effect against benign antigens and or stimulating a regulatory immune response characterized by the production of T helper cells 2 (Th2), T regulatory helper cells (TREG) and certain cytokines, including, but not limited to interleukin 10 (IL-10), as a therapy or prophylaxis of allergy and other IgE-mediated disorders, which are marked by an inappropriate IgE immune response including, but not limited to an aberrant and or enhanced IgE antibody production to benign antigens. The invention presents using helminth compound by administering it in a frequency and amount sufficient to eliminate or ameliorate the inappropriate immune response in an asthmatic and or allergic individual.

US Patent:

20190381160, Dec 19, 2019

Filed:

May 26, 2016

Appl. No.:

15/576178

Inventors:

- Princeton NJ, US
Kyle PERRY - Lawrenceville NJ, US
Michael F. PRINCIOTTA - Hightstown NJ, US
Daniel J O'CONNOR - Pennington NJ, US

Assignee:

Advaxis, Inc. - Princeton NJ

International Classification:

A61K 39/02
C12Q 1/6886
C12N 15/74
C12N 15/62
C12N 1/20
C07K 14/195
A61K 39/00
C12N 7/00
A61P 35/00

Abstract:

This invention provides a system of providing and creating personalized immunotherapeutic compositions for a subject having a disease or condition, including therapeutic immunotherapy delivery vectors and methods of making the same comprising gene expression constructs expressing peptides associated with one or more neo-epitopes or peptides containing mutations that are specific to a subject's cancer or unhealthy tissue. A delivery vector of this invention includes bacterial vectors including bacterial vectors; or viral vectors, peptide immunotherapy vectors; or DNA immunotherapy vectors, comprising one or more fusion proteins comprising one or more peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject. This invention also provides methods of using the same for inducing an immune response against a disease or condition, including a tumor or cancer, or an infection, or an autoimmune disease or an organ transplant rejection in the subject.